growth goe anoth gear higher balanc
perform pt
post beat anoth surg urolift coupl strong growth
across segment vascular surgeri balanc perform drove organ
growth ex-sel day nearli new multi-year high despit fx higher
spend outlook call increment leverag come
beyond benefit growth settl higher gear think
premium deserv pt
new higher-growth gear display messag earli part last year
wait refer organ growth go settl vsi
neotract get bake fold recal lrp target issu late last year call
organ growth improv msd hsd far handili
exceed expect improv cc improv
adjust divestitur sell day although urolift big driver
out-performance contribut growth sever area base busi
also notabl uptick vascular access improv cc cc last
combo ez-io uptak distributor stock describ revers de-
cc last year better perform sever vsi line biolog micro-
cathet guide-lin along resurg intra-aort balloon pump iabp
legaci busi latter saw growth iabp indic
faster uptak consol introduc last year compani note yet
seen posit impact iabp recal recent announc competitor
margins/ep fx/spend take small hit signific leverag still come adj
om touch actual predominantli fx affect
growth also higher spend lesser extent tariff
three set extend back half full-year adj om outlook lower
revis although ep left unchang spend side
equat dollar alloc ul form sale commiss
market promis drive substanti leverag go
forward new user transit higher-volum site coupl gain
restructur mix still support hit adj
om expans target bake current lrp
rais pt higher growth profil deserv premium goe
prior reflect higher ul revis
prior vascular access revis prior off-set higher
fx headwind spend ul still acceler legaci provid healthi
contribut increas balanc sheet flexibl sustain hsd top-lin
profil path ep clearer support premium valuat
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
gener earn estim reflect cash ep calcul
gener earn estim reflect cash ep calcul
msd organ growth annual om
contribut urolift
limit market releas launch percuv
manta repla launch
follow-on deal similar scale neotract near-
ep respect
hsd organ growth annual om
contribut urolift
higher contribut percuv manta
repla
follow-on deal similar scale neotract near-term
ep respect
bull case pt assum adj ep
lsd organ growth annual om
sub contribut urolift
deceler growth increas competit
delay market releas percuv manta
follow-on deal similar scale neotract
ep respect
buy thesi predic best-in-class
report organ top-lin growth profil rel
peer continu upsid adjust om
restructur balanc sheet flexibl
posit one better
posit mid-cap hospit suppli provid
compani increasingli attract larger
deep-div analysi neotract acquisit doc
survey along detail bottom-up analysi
success bla trial clearanc repla
launch percuv manta
pleas see import disclosur inform page report
urolift still earli part growth phase plenti
driver come
urolift reach anoth new high growth improv last
contribut last combin physician train dtc
advertis drive patient pull-through expand payor coverag favor
clinic data releases/publ train side compani target
newli train urologist year-end increment exit last
would bring total penetr activ bph surgeon
total urologist term reimburs compani
secur coverag ul across medicar beneficiari region nation
commerci plan independ bcb license henc coverag virtual
nationwid follow recent sign data front saw sever new
studi present aua earli may includ real-world outcom studi show
data patient treat ul across na australia site expect
data equival lift studi despit much larger
divers patient sampl improv ipp intern prostat symptom
score improv qmax peak urinari flow rate improv qualiti
life measur low rate sexual dysfunct ul versu average
surgic treatment low re-surg intervent rate ul
despit current hockey stick growth outlook ul still expans consid
low penetr bph treatment pool ytd run-rat suggest less
penetr core annual bph drug-therapi cohort pend launch
still track late full user convers eventu entri japan
also track mid-to-l soft launch think latter two particular
underappreci point consid user featur like foster wider
uptak ease-of-us benefit japan repres second-largest market term
bph preval urologist estim annual look traction
date coupl becom increasingli confid neotract
deliv sale mileston exit meet/surpass
peak sale target time
pleas see import disclosur inform page report
pleas see import disclosur inform page report
